IMB Dx secures $3.7M in government loans for R&D and expansion
What's the deal? South Korean diagnostics firm IMB Dx has secured 5 billion KRW (roughly $3.7 million) in policy financing through a technology innovation loan program run by the Ministry of Trade, Industry and EnergyDealroom has a profile for this one. Try Dealroom →. The company announced the debt financing on September 1.
The terms: The loan carries an interest rate of about 1%, with a two-year grace period followed by three years of installment repayment. IMB Dx said the structure lets it fund investment without near-term principal repayment pressure.
What's the endgame? IMB Dx develops liquid biopsy-based precision diagnostics. It plans to use the funds to strengthen research, development, and clinical work, and to accelerate its expansion at home and abroad.
Why now? The company framed the financing as a way to lock in growth capital at low cost. "Securing funds needed for growth on stable and efficient terms is also an important management task," said chief operating officer Kim Si-yeon (translated from Korean).
Kim added that the company's technology and future value had been "recognised by both government ministries and the state bank," pledging to deliver "tangible results."
The signal: The deal shows how state-backed lending can offer growth-stage biotech firms a lower-cost alternative to equity financing, preserving cash flow while advancing capital-intensive R&D and clinical programs.
Read more: edaily.co.kr
Image credit: US Army Africa
